CG
CTMX icon

Cutler Group’s CytomX Therapeutics CTMX Stock Holding History

Cutler Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000
Closed -$3K – 4904
2020
Q3 		$3K Sell
1,000
-200
-17% -$1.48K ﹤0.01% 3795
2020
Q2 		$3K Buy
+1,200
New +$11.1K ﹤0.01% 3581
2019
Q2 		– Sell
-700
Closed -$5K – 4301
2019
Q1 		$5K Hold
700
– – ﹤0.01% 2890
2018
Q4 		$2K Sell
700
-400
-36% -$5.93K ﹤0.01% 3331
2018
Q3 		$7K Buy
1,100
+400
+57% +$9.11K ﹤0.01% 2848
2018
Q2 		$6K Buy
700
+100
+17% +$2.55K ﹤0.01% 2977
2018
Q1 		$1K Sell
600
-200
-25% -$5.71K ﹤0.01% 4000
2017
Q4 		$1K Buy
+800
New +$16.6K ﹤0.01% 4404

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cutler Group's CTMX Position: Q1 2024 in Review

Cutler Group sold out of CytomX Therapeutics (CTMX) in Q1 2024, closing a stake of 1,000 shares — an estimated $1K sold.

Cutler Group first reported a position in CTMX in Q4 2017 and held it in 23 quarters. The position peaked at $15K in Q4 2018. 88 funds tracked by Wall St. Rank hold CTMX as of Q1 2024.

  • Cutler Group reported no remaining CytomX Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1,000 CytomX Therapeutics shares in Q1 2024, an estimated $1K.
  • Cutler Group first reported a position in CytomX Therapeutics in Q4 2017 and held it in 23 quarters.
  • Cutler Group's CytomX Therapeutics position peaked at $15K in Q4 2018.
  • 88 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.